Ultragenyx Pharmaceutical Inc. (RARE) Stock
Key stats
- Market cap
- $1.70B
- Price / Earnings ratio
- -3.1x
- EPS (TTM)
- -$5.18
- Volume
- Loading
- 52-week high
- $39.89
- 52-week low
- $12.73
Source: third-party data provider, as of November 13, 2026
Compare with RARE
Recent news

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
RARE

Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
RARE

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
RARE

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
RARE
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 53.73
- MACD 12/26/9
- 0.05
- EMA 9 of MACD
- -0.03
- MACD histogram
- 0.08
- SMA 50
- $15.47
- Price above SMA 50
- EMA 50
- $17.21
- Price below EMA 50
- SMA 200
- $22.61
- Price below SMA 200
- EMA 200
- $22.02
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 18 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.04 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
RARE

Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
RARE

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
RARE

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
RARE

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
RARE

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
RARE

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
RARE

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
RARE

Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
RARE

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
RARE
News tone: automated (AI) classification of the article's content, not a price prediction.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 1960 |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | 1979 |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 1978 |
| Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer | 1970 |
| Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP | 1973 |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | 1971 |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | 1965 |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 1965 |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations | — |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 1966 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 53.73
- MACD 12/26/9
- 0.05
- EMA 9 of MACD
- -0.03
- MACD histogram
- 0.08
- SMA 50
- $15.47
- Price above SMA 50
- EMA 50
- $17.21
- Price below EMA 50
- SMA 200
- $22.61
- Price below SMA 200
- EMA 200
- $22.02
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
18 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $16.00
- Average
- $28.76
- High
- $74.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.6 | +10.4 | ||||||||||
| 2022 | -17.1 | -6.6 | +7.8 | -8.6 | -35.1 | +29.3 | -15.0 | -5.8 | -14.6 | -3.5 | -13.4 | +22.5 |
| 2023 | -0.4 | -1.7 | -12.2 | +7.9 | +12.1 | -7.0 | -7.6 | -14.3 | -5.6 | +1.7 | +7.8 | +19.1 |
| 2024 | -8.4 | +17.3 | -13.0 | -9.4 | -7.3 | -0.1 | +9.5 | +28.6 | -0.3 | -9.8 | -6.6 | -11.6 |
| 2025 | +4.6 | -1.2 | -12.2 | +15.2 | -12.7 | +0.6 | -24.7 | +5.3 | -6.1 | +15.4 | +3.8 | -31.1 |
| 2026 | +2.0 | -5.5 | -9.0 | +15.3 | -3.4 | +46.1 | -23.1 | +0.8 | -41.8 | +9.2 | +2.5 |



